HTX Ventures Annual Review and Outlook: Regulatory Clarity, Asset Tokenization, and Institutional Adoption Resonate
PANAMA CITY, Jan. 28, 2026 /PRNewswire/ -- Recently, HTX Ventures, the global…
FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment…
HTX’s 2025 Listing Strategy Review, Building a High-Liquidity Ecosystem Through First-Mover Advantage and Longtermism
PANAMA CITY, Jan. 23, 2026 /PRNewswire/ -- In 2025, persistent macro uncertainty…
KuCoin Releases 2025 Annual Review: A Renewed Brand, a Year Built on Trust
PROVIDENCIALES, Turks and Caicos Islands, Dec. 30, 2025 /PRNewswire/ -- KuCoin today…
Charles Winslow Completes Annual Internal Strategic Review at Lumena Intelligent Alliance Office
Jersey City, NJ, Dec. 25, 2025 (GLOBE NEWSWIRE) -- Lumena Intelligent Alliance…
2025 in Review: Celebrating Each Trader’s Unique Journey on Bybit
DUBAI, UAE, Dec. 11, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency…
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
Media Release Event to be held virtually via live webcast and archived…
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
November 25, 2025 18:15 ET | Source: Ascendis Pharma – Prescription Drug…
Texan Artisinal Review: Context, Accuracy & Risk in NYC of Bisnow’s Real-Estate Reporting
Austin, Texas, Nov. 21, 2025 (GLOBE NEWSWIRE) -- In the fast-moving landscape…
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
November 18, 2025 16:30 ET | Source: Protara Therapeutics NEW YORK, Nov.…
